Cargando…

Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs

BACKGROUND: Arsenic exposure increases the risk of non-cancerous and cancerous diseases. In the Antofagasta region in Chile, an established relationship exists between arsenic exposure and the risk of cancer of the bladder, lung and skin. Platinum-based drugs are first-line treatments, and many work...

Descripción completa

Detalles Bibliográficos
Autores principales: Román, Domingo A, Pizarro, Isabel, Rivera, Lidia, Torres, Carolina, Ávila, Juan, Cortés, Pedro, Gill, Marjorie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432591/
https://www.ncbi.nlm.nih.gov/pubmed/22546077
http://dx.doi.org/10.1186/1756-0500-5-207
_version_ 1782242228824965120
author Román, Domingo A
Pizarro, Isabel
Rivera, Lidia
Torres, Carolina
Ávila, Juan
Cortés, Pedro
Gill, Marjorie
author_facet Román, Domingo A
Pizarro, Isabel
Rivera, Lidia
Torres, Carolina
Ávila, Juan
Cortés, Pedro
Gill, Marjorie
author_sort Román, Domingo A
collection PubMed
description BACKGROUND: Arsenic exposure increases the risk of non-cancerous and cancerous diseases. In the Antofagasta region in Chile, an established relationship exists between arsenic exposure and the risk of cancer of the bladder, lung and skin. Platinum-based drugs are first-line treatments, and many works recognise selenium as a cancer-fighting nutrient. We characterised the short-term urinary excretion amounts of arsenic, selenium and platinum in 24-h urine samples from patients with lung cancer and those with cancer other than lung treated with cisplatin or/and carboplatin. As - Se - Pt inter-element relationships were also investigated. RESULTS: The amounts of platinum excreted in urine were not significantly different between patients with lung cancer and those with other cancers treated with cisplatin, despite the significant variation in platinum amounts supplied from platinum-based drugs. In general, the analytical amounts of excreted selenium were greater than those for arsenic, which could imply that platinum favours the excretion of selenium. For other types of cancers treated with drugs without platinum, excretion of selenium was also greater than that of arsenic, suggesting an antagonist selenium-anti-cancer drug relationship. CONCLUSIONS: Regards the baseline status of patients, the analytical amounts of excreted Se is greater than those for As, particularly, for cisplatin chemotherapy. This finding could imply that for over the As displacement Pt favours the excretion of Se. The analytical amounts of excreted Se were greater than those for As, either with and without Pt-containing drugs, suggesting an antagonist Se-anti-cancer drug relationship. However, it seemed that differences existed between As - Se - Pt inter-element associations in patients treated for lung cancer in comparison with those treated for cancer other than lung. Therefore, knowledge obtained in this work, can contribute to understanding the arsenic cancer mechanism and the As - Se - Pt inter-element association for lung cancer and other types of cancer, which in some cases respond at a linear mathematical model.
format Online
Article
Text
id pubmed-3432591
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-34325912012-09-04 Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs Román, Domingo A Pizarro, Isabel Rivera, Lidia Torres, Carolina Ávila, Juan Cortés, Pedro Gill, Marjorie BMC Res Notes Research Article BACKGROUND: Arsenic exposure increases the risk of non-cancerous and cancerous diseases. In the Antofagasta region in Chile, an established relationship exists between arsenic exposure and the risk of cancer of the bladder, lung and skin. Platinum-based drugs are first-line treatments, and many works recognise selenium as a cancer-fighting nutrient. We characterised the short-term urinary excretion amounts of arsenic, selenium and platinum in 24-h urine samples from patients with lung cancer and those with cancer other than lung treated with cisplatin or/and carboplatin. As - Se - Pt inter-element relationships were also investigated. RESULTS: The amounts of platinum excreted in urine were not significantly different between patients with lung cancer and those with other cancers treated with cisplatin, despite the significant variation in platinum amounts supplied from platinum-based drugs. In general, the analytical amounts of excreted selenium were greater than those for arsenic, which could imply that platinum favours the excretion of selenium. For other types of cancers treated with drugs without platinum, excretion of selenium was also greater than that of arsenic, suggesting an antagonist selenium-anti-cancer drug relationship. CONCLUSIONS: Regards the baseline status of patients, the analytical amounts of excreted Se is greater than those for As, particularly, for cisplatin chemotherapy. This finding could imply that for over the As displacement Pt favours the excretion of Se. The analytical amounts of excreted Se were greater than those for As, either with and without Pt-containing drugs, suggesting an antagonist Se-anti-cancer drug relationship. However, it seemed that differences existed between As - Se - Pt inter-element associations in patients treated for lung cancer in comparison with those treated for cancer other than lung. Therefore, knowledge obtained in this work, can contribute to understanding the arsenic cancer mechanism and the As - Se - Pt inter-element association for lung cancer and other types of cancer, which in some cases respond at a linear mathematical model. BioMed Central 2012-04-30 /pmc/articles/PMC3432591/ /pubmed/22546077 http://dx.doi.org/10.1186/1756-0500-5-207 Text en Copyright ©2012 Roman et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Román, Domingo A
Pizarro, Isabel
Rivera, Lidia
Torres, Carolina
Ávila, Juan
Cortés, Pedro
Gill, Marjorie
Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs
title Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs
title_full Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs
title_fullStr Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs
title_full_unstemmed Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs
title_short Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs
title_sort urinary excretion of platinum, arsenic and selenium of cancer patients from the antofagasta region in chile treated with platinum-based drugs
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432591/
https://www.ncbi.nlm.nih.gov/pubmed/22546077
http://dx.doi.org/10.1186/1756-0500-5-207
work_keys_str_mv AT romandomingoa urinaryexcretionofplatinumarsenicandseleniumofcancerpatientsfromtheantofagastaregioninchiletreatedwithplatinumbaseddrugs
AT pizarroisabel urinaryexcretionofplatinumarsenicandseleniumofcancerpatientsfromtheantofagastaregioninchiletreatedwithplatinumbaseddrugs
AT riveralidia urinaryexcretionofplatinumarsenicandseleniumofcancerpatientsfromtheantofagastaregioninchiletreatedwithplatinumbaseddrugs
AT torrescarolina urinaryexcretionofplatinumarsenicandseleniumofcancerpatientsfromtheantofagastaregioninchiletreatedwithplatinumbaseddrugs
AT avilajuan urinaryexcretionofplatinumarsenicandseleniumofcancerpatientsfromtheantofagastaregioninchiletreatedwithplatinumbaseddrugs
AT cortespedro urinaryexcretionofplatinumarsenicandseleniumofcancerpatientsfromtheantofagastaregioninchiletreatedwithplatinumbaseddrugs
AT gillmarjorie urinaryexcretionofplatinumarsenicandseleniumofcancerpatientsfromtheantofagastaregioninchiletreatedwithplatinumbaseddrugs